Overview

Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+ABC
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Fulvestrant